Annexon (ANNX) Projected to Release Earnings on Monday

Key Points

• Annexon is expected to report Q3 2026 results before Monday’s market open, with analysts projecting a loss of $0.28 per share and revenue of $3.50 million. The earnings conference call is scheduled for November 12 at 12:30 p.m. ET.
• The company reported a larger-than-expected loss in the prior quarter, and analysts forecast losses of $1.05 per share for the current fiscal year and $0.84 for the next.
• ANNX shares opened at $4.05, well below the average analyst price target of $15.29. Ratings are mixed, though six analysts rate the stock a Buy; CEO Douglas Love recently purchased nearly 26,100 shares.

Annexon (NASDAQ:ANNX - Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Annexon to announce earnings of ($0.28) per share and revenue of $3.50 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Annexon (NASDAQ:ANNX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.04). On average, analysts expect Annexon to post ($1.05) EPS for the current fiscal year and ($0.84) EPS for the next fiscal year.

Annexon Stock Performance

Shares of ANNX opened at $4.05 on Monday. The stock has a market capitalization of $767.80 million, a P/E ratio of -3.49 and a beta of 1.43. Annexon has a 1 year low of $2.54 and a 1 year high of $7.18. The company's fifty day moving average is $4.20 and its two-hundred day moving average is $5.23.

Analyst Ratings Changes

Several research analysts recently weighed in on ANNX shares. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 target price on shares of Annexon in a research report on Monday, July 20th. Wall Street Zen lowered Annexon from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Needham & Company LLC raised their target price on Annexon from $11.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Citizens Jmp raised shares of Annexon from an "underperform" rating to a "market perform" rating in a report on Thursday, August 13th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Annexon from $14.00 to $15.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 30th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $15.29.

Insider Activity

In other Annexon news, CEO Douglas Love bought 26,065 shares of the stock in a transaction dated Thursday, September 24th. The stock was bought at an average cost of $3.83 per share, for a total transaction of $99,828.95. Following the completion of the purchase, the chief executive officer owned 390,476 shares in the company, valued at $1,495,523.08. This represents a 7.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.31% of the company's stock.

About Annexon

Annexon, Inc NASDAQ: ANNX is a clinical-stage biotechnology company developing therapies for diseases associated with abnormal activation of the classical complement pathway. The company's approach is designed to selectively inhibit complement activity while preserving the immune system's ability to perform essential functions.

Annexon's pipeline has included ANX005, a monoclonal antibody targeting C1q, the initiating protein of the classical complement pathway. The company has evaluated ANX005 in immune-mediated and neuroinflammatory disorders, including Guillain-Barré syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.